Esbriet

Active substance

Pirfenidon

Holder

Roche

Status

Running

Indication

Treatment of adult patients with unclassifiable interstitial lung disease (uILD) and who exit trial MA39189.

Documents publics

Approbation

Information for the patient

Informed consent

Last update

10/05/2021

Last updated on 10/05/2021